Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

SESilvia Escribano-SerratSHShimrit HarlevAGAndrè Goy

Discussion

Loading...

Member takes

Overview

Multicenter study reveals salvage therapies improve progression-free survival in relapsed large B-cell lymphoma, suggesting effective strategies post CAR-T.

Key Points

  • To assess the effectiveness of first-line salvage therapies and their impact on survival in relapsed large B-cell lymphoma after CAR-T therapy.
  • International, multicenter retrospective cohort study with patients treated at five institutions.
  • Patients received 2nd or 3rd line CAR-T therapy; efficacy assessed via Lugano criteria.
  • Cox regression models analyzed prognostic factors affecting survival outcomes.
  • 1-year overall survival rate was 47%, with progression-free survival at 29%.
  • Salvage therapies yielded complete responses in a notable proportion of patients.
  • Common treatments included bispecifics and bendamustine, with variable response rates.

Cite This Study

Escribano-Serrat et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df35https://doi.org/10.1182/blood-2025-3711
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry2025
  2. 2Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group2026
  3. 3Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models2025
  4. 4Improved survival with third-line CAR-T therapy vs alternative treatment in DLBCL: A propensity score–matching analysis2025
  5. 5Real-World Treatment Patterns of Patients with Large B-cell Lymphoma Over Time and into a Post-CAR T Approval Era2026